It is more likely that patients using SGLT-2is might have more severe diabetes than patients using other second- to third-line antidiabetic drugs in our study, since users of SGLT-2is had a longer duration of diabetes and a higher prevalence of insulin use compared with users of other second- to third-line antidiabetic drugs at cohort entry in our study (Table 1). The gene discussed is INS; the disease is diabetes mellitus.